We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$177M
AUM Growth
-$67.5M
(-28%)
Cap. Flow
-$79M
Cap. Flow % of AUM
Cap. Flow %
-44.69%
Top 10 Holdings %
Top 10 Hldgs %
45.17%
Holding
74
New
27
Increased
–
Reduced
22
Closed
22
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$9.29M |
| 2 |
Boston Scientific
BSX
|
+$7.9M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$7.44M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$6.11M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$5.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$12.2M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$10.1M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$10.1M |
| 4 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$7.85M |
| 5 |
bluebird bio
BLUE
|
+$7.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.01% |
| 2 | Miscellaneous | 36.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $11M | 6.25% |
+220,000
| New | +$11.4M |
2016 Q1
0 quarters
|
|
2
PUT
Acadia Pharmaceuticals
ACAD
$2.85B
| $9.8M | 5.54% |
+350,000
| New | +$7.63M |
2016 Q1
0 quarters
|
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $9.03M | 5.11% |
+90,202
| New | +$9.29M |
2016 Q1
0 quarters
|
|
4
CALL
Edwards Lifesciences
EW
$60.2B
| $8.82M | 4.99% |
+300,000
| New | +$8.28M |
2016 Q1
0 quarters
|
|
|
5
Boston Scientific
BSX
$63.8B
| $8.46M | 4.79% |
+450,000
| New | +$7.9M |
2016 Q1
0 quarters
|
|
6
PUT
iShares Russell 2000 ETF
IWM
$78.5B
| $8.3M | 4.7% |
+75,000
| New | +$7.76M |
2016 Q1
0 quarters
|
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.04M | 3.98% |
+425,000
| New | +$7.44M |
2016 Q1
0 quarters
|
|
8
Pacific Biosciences
PACB
$734M
| $5.95M | 3.37% |
700,000
-50,000
| -7% | -$492K |
2015 Q4
1 quarter
|
|
9
CALL
AbbVie
ABBV
$518B
| $5.71M | 3.23% |
+100,000
| New | +$5.57M |
2016 Q1
0 quarters
|
|
|
10
Agios Pharmaceuticals
AGIO
$1.88B
| $5.68M | 3.22% |
+140,000
| New | +$5.99M |
2016 Q1
0 quarters
|
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.57M | 3.15% |
+40,000
| New | +$5.87M |
2016 Q1
0 quarters
|
|
12
CALL
Teva Pharmaceutical Industries Limited
TEVA
$50.1B
| $5.35M | 3.03% |
+100,000
| New | +$5.87M |
2016 Q1
0 quarters
|
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.35M | 3.03% |
250,000
| – | – |
2015 Q4
1 quarter
|
|
14
DELISTED
Sage Therapeutics
SAGE
| $5.13M | 2.9% |
160,000
-40,000
| -20% | -$1.41M |
2015 Q1
4 quarters
|
|
|
SPNC
15
DELISTED
Spectranetics Corp
SPNC
| $5.08M | 2.88% |
350,000
-85,000
| -20% | -$1.18M |
2015 Q3
2 quarters
|
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.07M | 2.87% |
+120,000
| New | +$6.11M |
2016 Q1
0 quarters
|
|
17
iShares US Healthcare Providers ETF
IHF
$1.48B
| $4.82M | 2.73% |
+197,500
| New | +$4.6M |
2016 Q1
0 quarters
|
|
18
DELISTED
NEVRO CORP.
NVRO
| $4.22M | 2.39% |
75,000
-10,000
| -12% | -$590K |
2015 Q4
1 quarter
|
|
|
NSTG
19
DELISTED
NanoString Technologies, Inc.
NSTG
| $3.42M | 1.94% |
225,000
-175,000
| -44% | -$2.47M |
2014 Q1
8 quarters
|
|
|
NUVA
20
DELISTED
NuVasive, Inc.
NUVA
| $3.41M | 1.93% |
70,000
-160,000
| -70% | -$7.26M |
2014 Q3
6 quarters
|
|
21
Integra LifeSciences
IART
$1.12B
| $3.37M | 1.91% |
100,000
-140,000
| -58% | -$4.36M |
2015 Q3
2 quarters
|
|
22
BioMarin Pharmaceuticals
BMRN
$11.1B
| $3.3M | 1.87% |
+40,000
| New | +$3.25M |
2016 Q1
0 quarters
|
|
23
iShares US Medical Devices ETF
IHI
$4.1B
| $3.06M | 1.73% |
+150,000
| New | +$2.91M |
2016 Q1
0 quarters
|
|
24
ResMed
RMD
$33.2B
| $2.89M | 1.64% |
+50,000
| New | +$2.83M |
2016 Q1
0 quarters
|
|
25
CALL
Bausch Health
BHC
$3.14B
| $2.63M | 1.49% |
+100,000
| New | +$7.4M |
2016 Q1
0 quarters
|
|
Similar funds
AFS
E
Ghost Tree Capital's Q1 2016 Portfolio in Review
As of Q1 2016, Ghost Tree Capital held 74 positions worth $177M, down 28% from $244M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Ghost Tree Capital withdrew a net $79M in Q1 2016, closing 22 positions and reducing 22 holdings. Its most notable exit was Amgen, an estimated $12.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 96% a quarter earlier, followed by Miscellaneous.
Against the trend, Ghost Tree Capital opened a new position in Celgene Corp worth $9.03M.
- Ghost Tree Capital's largest Q1 2016 buy was Celgene Corp: 90,202 shares worth $9.03M.
- Ghost Tree Capital's biggest Q1 2016 reduction was NuVasive, Inc., cutting an estimated $7.26M.
- Ghost Tree Capital fully exited Amgen in Q1 2016, selling an estimated $12.2M.
- Ghost Tree Capital's ten largest holdings make up 45% of its $177M portfolio in Q1 2016.
- Ghost Tree Capital opened 27 new positions and closed 22 in Q1 2016.
- Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $177M.
Based on Ghost Tree Capital's 13F filing for Q1 2016, filed 13 May 2016.